{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:18:08Z","timestamp":1784585888214,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ijcard.2016.03.186","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T06:16:40Z","timestamp":1459750600000},"page":"301-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses"],"prefix":"10.1016","volume":"214","author":[{"given":"Hidekatsu","family":"Fukuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Wakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ohte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.03.186_bb0005","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0735-1097(99)00118-7","article-title":"Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort","volume":"33","author":"Vasan","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0015","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1253\/circj.CJ-09-0254","article-title":"Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)","volume":"73","author":"Tsuchihashi-Makaya","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0020","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0025","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0040","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/HJH.0000000000000184","article-title":"Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats","volume":"32","author":"Akahori","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0045","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjhf\/hfq101","article-title":"Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction","volume":"12","author":"Gomez-Garre","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/hc2801.094031","article-title":"Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy","volume":"104","author":"Patel","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0055","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/01.CIR.0000034047.70205.97","article-title":"Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation","volume":"106","author":"Indolfi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0060","doi-asserted-by":"crossref","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0065","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1161\/01.CIR.0000164260.82417.3F","article-title":"Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans","volume":"111","author":"Landmesser","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0070","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0735-1097(02)01717-5","article-title":"Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension","volume":"39","author":"Ferrier","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2362.2000.00654.x","article-title":"The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia","volume":"30","author":"Smilde","year":"2000","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0080","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.arcmed.2010.08.009","article-title":"Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials","volume":"41","author":"Zhang","year":"2010","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0085","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/hc1202.105290","article-title":"New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment","volume":"105","author":"Zile","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0090","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","article-title":"New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes","volume":"35","author":"Senni","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.104.519876","article-title":"Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report","volume":"112","author":"Fukuta","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0100","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2143\/AC.63.6.2033384","article-title":"Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function\u2013a preliminary report","volume":"63","author":"Roik","year":"2008","journal-title":"Acta Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjcard.2007.08.050","article-title":"Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function","volume":"101","author":"Shah","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cardfail.2008.10.026","article-title":"Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis","volume":"15","author":"Ouzounian","year":"2009","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0115","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/clc.20615","article-title":"Statin therapy in patients with diastolic heart failure","volume":"33","author":"Tehrani","year":"2010","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0120","first-page":"602","article-title":"Prognostic factors and long-term survival after initial diagnosis of heart failure","volume":"138","author":"Quiros","year":"2012","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jjcc.2013.03.013","article-title":"Clinical characteristics and long-term clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction: a prospective cohort of Shinken Database 2004-2011","volume":"62","author":"Kaneko","year":"2013","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0130","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2013.12.023","article-title":"Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction","volume":"113","author":"Liu","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0135","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The Propensity Score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jtcvs.2009.12.022","article-title":"von SB, Borgermann J: Off-pump versus on-pump coronary artery bypass grafting: a systematic review and meta-analysis of propensity score analyses","volume":"140","author":"Kuss","year":"2010","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0145","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1253\/circj.CJ-14-0865","article-title":"Prognostic impact of statin use in patients with heart failure and preserved ejection fraction","volume":"79","author":"Nochioka","year":"2015","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0150","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of >\/=50","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0160","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0165","first-page":"1383","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0170","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0175","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0180","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJM199502233320807","article-title":"Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms","volume":"332","author":"Levine","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0185","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0190","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJMcp022709","article-title":"Clinical practice. Diastolic heart failure","volume":"351","author":"Aurigemma","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0195","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMp048064","article-title":"Understanding \"diastolic\" heart failure","volume":"350","author":"Redfield","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0200","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.RES.47.3.425","article-title":"Reduction in pulse wave velocity and improvement of aortic distensibility accompanying regression of atherosclerosis in the rhesus monkey","volume":"47","author":"Farrar","year":"1980","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0205","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/01.CIR.0000041255.88750.F0","article-title":"Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging","volume":"106","author":"Corti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0210","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0735-1097(01)01452-8","article-title":"Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance","volume":"38","author":"O'Rourke","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0215","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/01.RES.0000129254.25507.d6","article-title":"What mechanisms underlie diastolic dysfunction in heart failure?","volume":"94","author":"Kass","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0220","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/hc3401.095946","article-title":"Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction","volume":"104","author":"Bauersachs","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0225","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/hc0702.104164","article-title":"Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction","volume":"105","author":"Hayashidani","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0230","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jacc.2007.04.050","article-title":"Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure","volume":"50","author":"Zaca","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0235","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.fjc.0000211791.22411.0d","article-title":"Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure","volume":"47","author":"Saka","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0240","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.cardiores.2005.08.001","article-title":"Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure","volume":"69","author":"Ichihara","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0245","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.amjcard.2003.08.040","article-title":"Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease","volume":"92","author":"Young-Xu","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0250","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.amjcard.2003.08.023","article-title":"Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion","volume":"92","author":"Siu","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0255","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/CIRCULATIONAHA.106.621763","article-title":"Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study","volume":"114","author":"Patti","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0260","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ahj.2007.07.015","article-title":"Statin use and recurrence of atrial fibrillation after successful cardioversion","volume":"154","author":"Humphries","year":"2007","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0265","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0735-1097(03)00498-4","article-title":"Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial","volume":"42","author":"Mitchell","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0270","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jacc.2005.09.053","article-title":"Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II","volume":"47","author":"Vyas","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0275","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","article-title":"Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST)","volume":"103","author":"Deswal","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0280","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1161\/01.CIR.102.25.3060","article-title":"Plasma cytokine parameters and mortality in patients with chronic heart failure","volume":"102","author":"Rauchhaus","year":"2000","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2016.03.186_bb0285","doi-asserted-by":"crossref","first-page":"SI34","DOI":"10.1016\/S0140-6736(98)90017-4","article-title":"New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress","volume":"352","author":"Givertz","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0290","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.jacc.2006.01.060","article-title":"Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"47","author":"Olsson","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0295","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/01.CIR.0000144474.65922.AA","article-title":"Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"110","author":"Solomon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0300","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1161\/CIRCULATIONAHA.105.561423","article-title":"Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients","volume":"112","author":"Solomon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.03.186_bb0305","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0310","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijcard.2016.03.186_bb0315","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/1755-5922.12150","article-title":"Effects of Statin Treatment on Inflammation and Cardiac function in Heart Failure: An Adjusted Indirect Comparison Meta-analysis of Randomised Trials","volume":"33","author":"Bonsu","year":"2015","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.ijcard.2016.03.186_bb0320","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.hlc.2014.05.005","article-title":"Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials","volume":"23","author":"Liu","year":"2014","journal-title":"Heart Lung Circ."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316306192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316306192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T13:05:10Z","timestamp":1718456710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316306192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":64,"alternative-id":["S0167527316306192"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.03.186","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.03.186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}